Deal Dynamics in Life Sciences: Compliance, Pricing, and Smart M&As
Join AFS Life Sciences Partner Stephanie Trunk and Darshan Kulkarni, Life Sciences regulatory and compliance attorney, to unpack the recent acceleration of mergers and acquisitions across the life sciences sector.
They examine why deal flow is increasing, why buyers are favoring asset purchases over mega-deals, and how drug pricing and compliance priorities under the Trump Administration are shaping decisions.
They also explore how rigorous due diligence can mitigate risk, where artificial intelligence (AI) may streamline diligence, and why intellectual property (IP) mapping to actual products remains a recurring gap. The discussion closes with practical insights on building a robust compliance culture and navigating an evolving health care enforcement landscape.
Key Takeaways
- Increasingly, buyers favor strategic, targeted acquisitions over mega-deals.
- Policy impacts from the Trump Administration influencing deal strategy.
- Heightened due diligence emphasis on compliance and pricing risks.
- Emerging role of AI to streamline due diligence workflows.
- Persistent gaps in IP diligence, including weak mapping to products.
Contacts
- Related Industries